PDS Biotechnology Corp (EU6.BE)
| Previous close | 2.7340 |
| Open | 2.8040 |
| Bid | 2.8840 x N/A |
| Ask | 3.0880 x N/A |
| Day's range | 2.7860 - 3.0020 |
| 52-week range | 2.4740 - 9.4600 |
| Volume | |
| Avg. volume | 12 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswirePDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial PRINCETON, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today anno
Simply Wall St.PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions
Key Insights Significant control over PDS Biotechnology by retail investors implies that the general public has more...
Insider MonkeyPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript March 27, 2024 PDS Biotechnology Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to PDS Biotech’s call to discuss the company’s Year-End 2023 Financial Results and […]
